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Abstract
Objectives: The management of patients with colorectal cancer (CRC) and synchronous colorectal liver
metastasis (CLM) remains controversial. The present study was conducted in order to assess the clinical
and economic impacts of managing synchronous CLM with a staged versus a simultaneous surgery
approach.
Methods: A total of 224 patients treated for synchronous CLM during 1990–2012 were identified in the
Johns Hopkins Hospital liver database. Data on clinicopathological features, perioperative outcomes and
total hospital charges (inflation-adjusted) were collected and analysed.
Results: Overall, 113 (50.4%) patients underwent staged surgery and 111 (49.6%) were submitted to a
simultaneous CRC and liver operation. At surgery, liver-directed therapy included hepatectomy (75.0%) or
combined resection and ablation (25.0%). Perioperative morbidity (30.0%) and mortality (1.3%) did not
differ between groups (both P > 0.05). Median total length of hospitalization was longer in the staged
(13 days) than the simultaneous (7 days) surgery group (P < 0.001). Median total hospital charges were
higher among patients undergoing staged surgery (US$61 938) than among those undergoing a simul-
taneous operation (US$34 114) (P < 0.01). Median (simultaneous, 32.4 months versus staged, 39.6
months; P = 0.65) and 5-year (simultaneous, 27% versus staged, 29%; P = 0.60) overall survival were
similar between groups.
Conclusions: Patients with synchronous CLM managed with either simultaneous or staged surgery
have comparable perioperative and longterm outcomes. However, patients treated with simultaneous
surgery spent an average of 6 days fewer in hospital, resulting in a reduction of median hospital charges
of US$27 824 (55.1%). When appropriate and technically feasible, the simultaneous surgery approach to
synchronous CLM should be preferred.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the
USA and almost one in 20 persons is diagnosed with the disease at
some point in life.1 It is expected that over 140 000 new cases of
CRC will have been diagnosed in 2013 and that they will result in
over 50 000 deaths.1 Although the use of surveillance colonoscopy
and other diagnostic techniques has significantly increased over
time, nearly one in four patients will have metastatic disease at the
time of presentation, with the liver being the most common site of
spread.2–5 Complete surgical resection provides the best hope for
longterm survival, but only approximately 20% of patients with
colorectal liver metastasis (CLM) are eligible for curative intent
resection.6 With improvements in operative technique, as well as
the advent and use of modern chemotherapy and liver-directed
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therapies, 5-year survival is estimated to range from 40% to 58%
in surgically resected patients with CLM.7–10
The optimal surgical management of patients with CRC and
synchronous CLM remains controversial. Complete surgical
resection with negative margins of both the primary and meta-
static tumours provides the best option for longterm survival. A
topic of debate, however, is the timing and sequence of operations.
Traditionally, many patients with resectable disease have under-
gone two separate staged operations: initial colorectal resection
of the primary tumour, followed by hepatic resection for the
metastatic disease at a later date (colorectal-first approach). More
recently, patients have been submitted to a reversed staged
approach in order to address the hepatic tumour burden first
(liver-first approach) and to prevent any delays in liver-directed
and systemic therapies.5,11 Finally, in patients with resectable
liver metastases at the time of diagnosis, several institutions
have advocated for a single operation addressing both the pri-
mary colorectal and metastatic liver tumours (simultaneous
approach).12–14 The potential benefits of a simultaneous approach
include a single operation and anaesthetic administration, as well
as perhaps a shorter overall hospital stay. The simultaneous per-
formance of colorectal and liver resections, however, increases the
complexity of the procedure. Furthermore, this potential for
increased complexity and greater length of operation has raised
concerns that the associated morbidity and mortality may be
higher with the simultaneous approach.12–14
In addition to the potential differences in morbidity, there may
be economic differences associated with a simultaneous versus a
staged approach to synchronous CLM. The increasing cost of
health care in the USA and worldwide necessitates a comprehen-
sive evaluation of the financial impact of treatment decisions in
addition to standard clinical outcomes. As such, several investiga-
tors have performed cost comparison analyses for various gynae-
cological,15 orthopaedic,16,17 vascular18 and general surgical19,20
operations, among others. The comparison of the economic
impacts associated with, respectively, a simultaneous versus a
staged approach in patients with synchronous CLM remains less
well studied. Thus, the present authors aimed to define the
perioperative and longterm outcomes of patients undergoing sur-
gical resection for synchronous CLM. Specifically, the present
study sought to compare the economic impacts of a simultaneous
versus a staged approach for patients with resectable synchronous
CLM using actual hospital charges at the study institution.
Materials and methods
All patients submitted to liver resection for synchronous CLM at
Johns Hopkins Hospital between 1990 and 2012 were identified
through a structured query of the liver database. Patients were
categorized based on operative approach: simultaneous (com-
bined colorectal/liver resection) and staged (either colorectal- or
liver-first approaches). Patients with synchronous CLM who
underwent a staged approach in which the initial colorectal
resection was performed at an outside hospital and the subse-
quent liver operation at Johns Hopkins Hospital were included in
the study cohort. Patients who underwent only an ablative pro-
cedure without concurrent hepatic resection were excluded from
analysis.
Standard clinicopathological data were collected on character-
istics including age, sex and comorbidities. Treatment data were
collected and included estimated operative blood loss, operative
time, and the type and timing of perioperative chemotherapy
and/or radiation if applicable. Tumour characteristics were
reported based on the tumour–node–metastasis (TNM) staging
system. Perioperative complications were recorded according to
the Clavien–Dindo classification system, in which a major com-
plication is classified as of Grade III or higher.21 Perioperative
90-day mortality22 and time to recurrence, if applicable, were cal-
culated from the date of liver resection and based on the date of
last follow-up. The Johns Hopkins University Institutional Review
Board approved the study.
Economic analysis
An economic comparison analysis was performed based on all
charges assessed during the index hospitalization(s). Total
charges were tabulated based on all hospital services provided,
including room and board, surgical and anaesthesia services,
medications, laboratory and radiology services, physical/
occupational/speech therapy, and other miscellaneous charges.
Charges were administered and calculated based on a fixed inter-
nal hospital fee to allow for a direct comparison between treat-
ment strategies.23 For patients who underwent a staged colorectal
resection at an outside institution, total charges were imputed
based on average charges assessed for all patients submitted to an
equivalent colorectal resection over the past 5 years at the study
institution. All values were inflation-adjusted and expressed in
2012 US dollars.
Statistical analysis
Discrete variables were described as medians with interquartile
ranges (IQRs). Categorical variables were noted as totals and fre-
quencies. Univariate comparisons were assessed using the chi-
squared or analysis of variance tests as appropriate. Univariate and
multivariate logistic regression models were constructed to deter-
mine the association of relevant clinicopathological and operative
factors (extent of hepatectomy) with perioperative complications.
Univariate and multivariate regression models were constructed
to assess the impacts of different clinicopathological and treat-
ment factors on overall inflation-adjusted hospital charges. The
most parsimonious models were created using a stepwise
approach that included factors that were of clinical importance or
were statistically significant on univariate analysis. Overall sur-
vival time was calculated from the date of the index liver resection
to the date of death. Survival adjusted for censoring was calculated
using the Kaplan–Meier method and median survival was com-
pared using the log-rank test. All analyses were carried out using
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stata Version 12.0 (StataCorp LP, College Station, TX, USA). A
P-value of <0.05 (two-tailed) was considered to indicate statistical
significance.
Results
Description of cohort
Between 1990 and 2012, 224 patients with synchronous CLM
underwent hepatic resection at Johns Hopkins Hospital. Among
these patients, 111 (49.6%) were managed with a simultaneous
approach, 105 (46.9%) patients underwent a colorectal-first
approach and very few (n = 8, 3.6%) were treated with a liver-first
approach (Table 1). The median patient age was 57 years (IQR:
49–67 years) and the majority of patients were male (n = 137,
61.2%). Most patients had a primary colonic tumour (n = 154,
68.8%), and about a third of patients (n = 70, 31.3%) had a
primary rectal tumour.At the time of colorectal resection, patients
most commonly underwent a hemi-colectomy (n = 102, 45.5%)
or low anterior resection (n = 58, 25.9%). On pathology, median
colorectal tumour size was 4 cm (IQR: 3–5 cm).Most patients had
a colorectal tumour that penetrated through the muscularis
propria (T3 tumours: n = 154, 72.3%) and nodal metastases were
common (>N1: n = 155, 71.8%). The colorectal margin status was
microscopically negative (R0) in the overwhelming majority of
patients (n = 161, 97.6%).
In terms of metastatic liver disease, most patients (n = 145,
65.3%) had unilobular disease with an average tumour burden
of two metastases (IQR: 1–4 tumours). The median size of the
largest metastatic liver lesion was 2.5 cm (IQR: 1.5–4.5 cm). At
the time of surgery, hepatic resection involved either a minor
(less than four Couinaud segments resected) or major (four or
more Couinaud segments resected) hepatectomy. An R0 hepatic
resection was achieved in the majority of patients (n = 192,
85.7%). Of note, nearly a quarter of patients (n = 55, 24.6%)
underwent concurrent ablation therapy in addition to surgical
resection.
Several clinicopathological and operative characteristics dif-
fered between patients undergoing a simultaneous versus a staged
approach. Rectal tumours were more common in patients under-
going a staged operation (colorectal-first: n = 36, 34.3%; liver-first:
n = 6, 75.0%) compared with patients undergoing a simultaneous
resection (n = 28, 25.2%) (P = 0.009). In addition, receipt of
neoadjuvant therapy was more common among patients under-
going a liver-first approach (n = 7, 87.5%) than among those
undergoing either a colorectal-first (n = 18, 17.1%) or simulta-
neous (n = 43, 38.7%) approach (P ≤ 0.001).At the time of hepatic
resection, patients undergoing a staged operation were also more
likely to undergo a major hepatic resection (n = 58, 51.3%) than
were patients submitted to a simultaneous approach (n = 26,
23.4%) (P < 0.001). The use of concurrent ablation therapy in
addition to surgical resection was comparable, however, among
patients undergoing a staged (n = 33, 29.2%) versus a simulta-
neous (n = 22, 19.8%) approach (P = 0.14).
Short- and longterm outcomes
Among the entire cohort, 67 patients experienced a perioperative
complication after either the colorectal, hepatic or simultaneous
operation, giving a perioperative complication incidence of
29.9% (Table 2). The overall incidence of complications did not
differ according to operative approach (simultaneous, n = 28,
25.2%; colorectal-first, n = 34, 32.4%; liver-first, n = 5, 62.5%;
P = 0.06). In the staged approach group, complications after
hepatic resection were more common: 11 patients (9.7%) experi-
enced a perioperative complication after colorectal resection, and
32 patients (28.3%) experienced a perioperative complication
after liver resection. The incidence of complications after
hepatic resection remained similar between the two groups after
stratifying by minor (simultaneous, n = 21, 24.7% versus staged,
n = 16, 29.1%; P = 0.57) and major (simultaneous, n = 7, 26.9%
versus staged, n = 16, 27.6%) hepatectomy (Table 3). Further-
more, the incidence of major complications (Grade III or higher)
was similar among those undergoing a minor (simultaneous,
n = 14, 16.5% versus staged, n = 8, 14.5%; P = 0.76) or major
(simultaneous, n = 6, 23.1% versus staged, n = 7, 12.1%; P = 0.20)
hepatectomy. After multivariable analysis, operative approach
(simultaneous versus staged) was not associated with an
increased risk for complications [odds ratio (OR) 0.80, 95% con-
fidence interval (CI) 0.44–1.45; P = 0.46]. In fact, only patients
undergoing a concurrent ablative procedure along with resection
were at higher risk for complications (OR 2.02, 95% CI 1.05–
3.89; P = 0.04) (Table 4).
The median total hospital length of stay (LoS) among
the entire cohort was 11 days (IQR: 7–14 days). Total LoS was
shorter in the simultaneous surgery than in the staged sur-
gery cohort [simultaneous, 7 days (IQR: 5–9 days); colorectal-
first, 13 days (IQR: 12–15 days); liver-first, 10 days (IQR: 9–12
days); P < 0.001] (Fig. 1). Perioperative 90-day mortality
occurred in three patients and rates did not differ between
groups; two patients (1.8%) in the staged cohort died after
hepatic resection and one patient (0.9%) died after simultaneous
resection (P = 0.21).
After a median follow-up of 14 months (IQR: 3–39 months),
tumour recurrence occurred in 56% of patients. Among these, 3%
experienced a recurrence at the primary tumour location, 58%
had intrahepatic recurrence, 19% had extrahepatic recurrence,
and 20% of patients experienced both intra- and extrahepatic
recurrence. Median time to recurrence was 25.9 months (95% CI
22.1–32.2 months) and did not differ between the simultaneous
and staged groups [simultaneous, 25.9 months (95% CI 20.0–32.4
months) versus staged, 25.2 months (95% CI 20.7–35.4 months);
P = 0.68]. Median overall survival among the cohort was 33.4
months (95% CI 26.0–42.2 months) and was similarly equivalent
between the two groups [simultaneous, 32.4 months (95% CI
23.9–41.4 months) versus staged, 39.6 months (95% CI 25.2–46.2
months); P = 0.60] (Fig. 2). Overall rates of 1-, 3- and 5-year
survival were 88.9%, 47.3% and 27.8%, respectively. Rates of 1-, 3-
and 5-year recurrence-free survival were 83.6%, 37.6% and
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20.3%, respectively. There was no difference in 5-year overall
(simultaneous, 27.0% versus staged, 29.0%) or recurrence-free
(simultaneous, 19.1% versus staged, 21.6%) survival based
on the surgical approach to synchronous CLM (both P > 0.05)
(Fig. 2).
Comparison of hospital charges for simultaneous
versus staged surgery
Mean ± standard deviation (SD) total hospital charges among the
entire cohort were US$48 151 ± 24 948. Patients undergoing a
simultaneous operation had overall lower total mean charges
Table 1 Clinicopathological characteristics of cohort
Total
(n = 224)
Simultaneous
(n = 111)
Colorectal first
(n = 105)
Liver first
(n = 8)
P-value
Age, years, median (IQR) 57 (49–67) 57 (47–69) 59 (51–65) 54 (47–55) 0.73
Male gender, n (%) 137 (61.2%) 66 (59.5%) 68 (64.8%) 3 (37.5%) 0.27
Preoperative chemotherapy, n (%) 68 (30.4%) 43 (38.7%) 18 (17.1%) 7 (87.5%) <0.001
Preoperative radiotherapy, n (%) 14 (6.3%) 5 (4.5%) 9 (8.6%) 0 0.35
Location of primary tumour, n (%) 0.009
Colon 154 (68.8%) 83 (74.8%) 69 (65.7%) 2 (25.0%)
Rectum 70 (31.2%) 28 (25.2%) 36 (34.3%) 6 (75.0%)
Colorectal resection, n (%) 0.004
Hemi-colectomy 102 (45.6%) 64 (57.6%) 38 (36.2%) 0
Sigmoidectomy 39 (17.4%) 15 (13.5%) 22 (21.0%) 2 (25.0%)
Low anterior resection 58 (25.9%) 20 (18.0%) 32 (30.5%) 6 (75.0%)
Abdominoperineal resection 15 (6.7%) 8 (7.2%) 7 (6.7%) 0
Subtotal/total 4 (1.8%) 2 (1.8%) 2 (1.9%) 0
Size of colorectal tumour, cm, median (IQR) 4 (3–5) 4 (3–5) 4 (3–6) 3 (1–3) <0.001
T-stage, n (%) 0.21
T1 5 (2.4%) 3 (2.7%) 2 (2.1%) 0
T2 22 (10.3%) 16 (14.4%) 5 (5.3%) 1 (12.5%)
T3 154 (72.3%) 72 (64.9%) 75 (79.8%) 7 (87.5%)
T4 32 (15.0%) 20 (18.0%) 12 (12.8%) 0
N-stage, n (%) 0.73
N0 61 (28.2%) 29 (26.6%) 31 (31.3%) 1 (12.5%)
N1 89 (41.2%) 47 (43.1%) 37 (37.4%) 5 (62.5%)
N2 65 (30.1%) 32 (29.4%) 31 (31.3%) 2 (25.0%)
N3 1 (0.5%) 1 (0.9%) 0 0
R0 colorectal resection, n (%) 161 (98.2%) 100 (98.0%) 55 (98.2%) 8 (100%) 0.52
Liver metastasis location, n (%) 0.54
Unilateral 145 (65.3%) 74 (67.9%) 67 (63.8%) 4 (50.0%)
Bilateral 77 (34.7%) 35 (32.1%) 38 (36.2%) 4 (50.0%)
Liver metastases, n, median (IQR) 2 (1–4) 2 (1–4) 2 (1–4) 4 (2–4) 0.72
Liver-directed therapy, n (%) 0.18
Resection only 165 (74.3%) 85 (78.0%) 76 (72.4%) 4 (50.0%)
Resection + ablation 55 (24.8%) 22 (20.2%) 29 (27.6%) 4 (50.0%)
Type of liver resection, n (%) 0.009
Wedge resection 126 (56.3%) 76 (68.5%) 46 (43.8%) 4 (50.0%)
Hemi-hepatectomy 71 (31.7%) 25 (22.5%) 43 (41.0%) 3 (37.5%)
Extended hemi-hepatectomy 27 (12.1%) 10 (9.0%) 16 (15.2%) 1 (12.5%)
R0 liver resection, n (%) 192 (85.7%) 94 (84.7%) 91 (86.7%) 7 (87.5%) 0.91
Extrahepatic metastasis, n (%) 35 (15.7%) 21 (19.1%) 14 (13.3%) 0 0.54
IQR, interquartile range.
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(US$34 114 ± 24 765) compared with patients undergoing staged
operations (US$61 938 ± 15 807). The difference in charges
between a simultaneous and a staged approach represented an
average saving of US$27 824 per patient (Fig. 3a). Among patients
undergoing staged operations, total charges were higher for the
hospitalization following colorectal resection (colorectal charges,
US$32 293 versus hepatic charges, US$29 331; P = 0.001). Total
hospital charges also varied significantly according to the type and
extent of colorectal (right/left hemi-colectomy, US$28 632 versus
low anterior resection, US$35 144 versus sigmoid, US$33 123; P =
0.004) resection. In a subset analysis examining only patients with
colon cancer lesions (i.e. excluding all patients with rectal
tumours), a similar difference in charges was noted. Specifically,
among patients with colon cancer, the total charges associated
with a simultaneous approach were US$36 144, whereas charges
for a staged approach were US$61 931 (P < 0.001). An additional
subset analysis of only patients treated in the era of ‘modern’
chemotherapy (2000 to the present) was then performed, which
similarly demonstrated a difference in total charges (simultaneous
surgery, US$38 199 versus staged surgery, US$63 018; P < 0.001).
Several clinicopathological and operative factors were associ-
ated with higher overall mean charges. Specifically, mean total
Table 2 Perioperative outcomes after colorectal and liver resection
Total
(n = 224)
Simultaneous
(n = 111)
Colorectal first
(n = 105)
Liver first
(n = 8)
P-value
Complications after colorectal resection, n (%) 11 (49.6%) – 9 (8.6%) 2 (0.3%) <0.001
Grades I and II 4 (36.4%) – 3 (33.3%) 1 (50.0%) 0.66
Grades III and IV 7 (63.6%) – 6 (66.7%) 1 (50.0%)
90-day mortality after colorectal resection, n (%) 3 (1.3%) – 0 0 0.21
LoS after colorectal resection, days, median (IQR) 4 (0–7.5) – 7.5 (7.5–7.5) 6 (5–7) <0.001
ICU LoS after colorectal resection, days, median (IQR) 0 (0–0) – 0 (0–0) 2 (2–3) <0.001
Complications after liver resection, n (%) 60 (26.8%) 28 (25.2%) 28 (26.7%) 4 (50.0%) 0.31
Grades I and II 22 (38.6%) 7 (25.9%) 12 (46.2%) 3 (75.0%) 0.10
Grades III and IV 35 (61.4%) 20 (74.1%) 14 (53.9%) 1 (25.0%)
90-day mortality after liver resection, n (%) 3 (1.3%) 1 (0.9%) 2 (1.9%) 0 0.07
LoS after liver resection, days, median (IQR) 3 (0–5) 7 (5–9) 5 (4–6) 5 (4–6) <0.001
ICU LoS after liver resection, days, median (IQR) 0 (0–1) 2 (2–3) 1 (1–2) 2 (1–3) 0.04
Total LoS, days, median (IQR) 11 (7–14) 7 (5–9) 13 (12–15) 10 (9–12) <0.001
Total ICU LoS, days, median (IQR) 1 (0–1) 2 (2–3) 2 (2–3) 2 (1–3) 0.10
Recurrence, n (%) 125 (55.8%) 57 (51.4%) 63 (60.0%) 5 (62.5%) 0.41
LoS, length of stay, IQR, interquartile range; ICU, intensive care unit.
Table 3 Complications after minor and major hepatectomy for colorectal liver metastasis
Simultaneous
(n = 111)
Staged
(n = 113)
P-value
Minor hepatectomy (<4 segments), n (%)
Total (n = 140) 85 55
No complication 64 (75.3%) 39 (70.9%)
Overall complications after liver surgery 21 (24.7%) 16 (29.1%) 0.57
Grades I and II 7 (8.2%) 8 (14.5%) 0.24
Grades III and IV 14 (16.5%) 8 (14.5%) 0.76
Mortality within 90 days 0 0
Major hepatectomy (≥4 segments), n (%)
Total (n = 84) 26 58
No complication 19 (73.1%) 42 (72.4%)
Overall complications after liver surgery 7 (26.9%) 16 (27.6%) 0.95
Grades I and II 0 7 (12.1%) 0.06
Grades III and IV 6 (23.1%) 7 (12.1%) 0.20
Mortality within 90 days 1 (3.8%) 2 (3.4%) 0.93
HPB 1121
HPB 2014, 16, 1117–1126 © 2014 International Hepato-Pancreato-Biliary Association
charges were higher in patients with bilateral hepatic disease
(bilateral disease, US$53 103 versus unilateral disease, US$45 761;
P = 0.04), as well as among those patients undergoing combined
resection and ablation (with ablation, US$56 999 versus resection
alone, US$45 536; P = 0.003). In addition, charges were higher
among patients undergoing a major hepatectomy (major
hepatectomy, US$54 510 versus minor hepatectomy, US$44 335;
P = 0.003) (Fig. 3a). On multivariate analysis, although tumour
location (unilateral versus bilateral) was not associated with
overall mean charge, combined resection plus ablation
(ΔUS$11 989; P = 0.003) and major hepatectomy (ΔUS$12 020;
P < 0.001) remained associated with a higher charge. In addi-
tion, although the occurrence of a perioperative complication
increased charges in both cohorts,mean charges were significantly
higher in patients who experienced a complication in the staged
cohort (simultaneous surgery, US$55 309 versus staged surgery,
US$69 413; P < 0.001). After adjusting for the extent of hepatic
resection and incidence of complications, charges remained
higher (ΔUS$25 176; P < 0.001) in the staged surgery cohort. The
higher charges in the staged surgery group were largely driven by
the increased LoS; each additional hospital day resulted in an
average increase of US$3581 (P < 0.001) in total charges. Interest-
ingly, after adjusting for total LoS, charges remained higher in
patients submitted to a staged approach (Fig. 3b).
Discussion
Improved screening efforts have resulted in the earlier diagnosis of
patients with CRC in the USA.24 Along with the declines in the
incidence of and mortality rates in CRC over the last several
decades, improved treatment strategies for CRC have emerged.24
Over a quarter of all patients with CRC will still present, however,
with synchronous CLM at the time of diagnosis and only one in
five will be eligible for curative intent resection.2–5 Complete
Table 4 Univariate and multivariate analysis of factors associated with complications
Variables Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age 1.00 0.98–1.02 0.78 NA – –
Female gender 1.09 0.61–1.96 0.77 NA – –
Rectal tumour 0.82 0.44–1.54 0.54 NA – –
>2 liver lesions 1.12 0.62–2.01 0.70 NA – –
Bilateral disease 1.42 0.78–2.57 0.25 NA – –
Simultaneous operation 0.64 0.36–1.14 0.13 0.80 0.44–1.45 0.46
Major hepatic resection 0.90 0.50–1.63 0.74 NA – –
Colorectal tumour size 0.91 0.77–1.09 0.31 NA – –
T-stage
T1 Ref NA – –
T2 1.5 0.14–16.27 0.74
T3 1.81 0.20–16.64 0.60
T4 1.82 0.18–18.41 0.61
Extrahepatic metastasis 0.53 0.22–1.29 0.16 0.59 0.24–1.46 0.25
Liver tumour size 1.07 0.97–1.18 0.16 1.07 0.97–1.19 0.18
Liver-directed therapy
Resection alone Ref
Resection + ablation 1.98 1.05–3.74 0.04 2.02 1.05–3.89 0.04
OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable.
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surgical excision of CLM represents the best chance for longterm
recurrence-free and overall survival.7–10 Whether patients with
synchronous CLM are best treated with a staged or a simultaneous
approach has been a long-debated topic. Although some surgeons
prefer a staged approach, other groups have argued for a simulta-
neous approach in view of improvements in surgical technique
and postoperative care.12–14 In fact, the present centre previously
reported outcomes in a multi-institution cohort of 1004 patients
with synchronous CLM and noted no difference in short- or
longterm outcomes among patients undergoing a simultaneous
procedure in comparison with patients submitted to a staged
approach.13 The current study expands on this previous work by
focusing on results from a single institution. In this way, the effects
of potential heterogeneity on clinical outcomes at the many dif-
ferent centres included in the previous study were avoided.
Perhaps, more importantly – unlike in the previous work – the
present study evaluated the economic impact of the simultaneous
versus staged approaches to synchronous CLM. Patients undergo-
ing a simultaneous resection for synchronous CLM were noted to
have rates of perioperative morbidity and mortality, as well as
longterm overall and disease-free survival, comparable with those
in patients undergoing staged surgery. Furthermore, patients
undergoing a simultaneous operation spent, on average, 6 days
fewer in hospital and had an associated average lower hospital
charge of US$27 824 per patient compared with patients who
underwent staged surgery.
Several previous studies have demonstrated that a simultaneous
approach to synchronous CLM can have outcomes comparable
with those of the classic staged approach.12–14 Data from the
current study corroborate that simultaneous surgery in patients
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with synchronous CLM is both safe and effective. Patients sub-
mitted to either a simultaneous or a staged approach had similar
rates of perioperative morbidity and 90-day mortality. Although
patients in the simultaneous surgery cohort were more likely to
have undergone a minor hepatectomy than patients in the staged
surgery cohort, the incidence of complications remained similar
between the two groups even after adjusting for the extent of
hepatectomy (Table 3). More importantly, the incidence of major
complications that caused a deviation from the standard postop-
erative course was equivalent in both groups. In fact, only patients
undergoing a combined resection and ablative procedure had a
higher risk for the occurrence of a complication. Specifically,
patients undergoing a concomitant ablation were approximately
twice as likely to experience a perioperative complication.
Although the reasons for this finding are undoubtedly multifac-
torial, they may relate to the fact that patients who underwent
resection and ablation had more extensive disease in the liver and
thus represented cases of increased complexity. With regard to
longterm outcomes, patients undergoing a simultaneous opera-
tion had overall and recurrence-free survival rates similar to those
of patients undergoing staged surgery. Specifically, median sur-
vival was 32.4 months in the simultaneous surgery cohort and
39.6 months in the staged surgery cohort (P = 0.65). Collectively,
the data would strongly suggest that the simultaneous resection of
synchronous CLM at the time of resection of the primary
colorectal lesion is both safe and as effective as staged surgery.
The approach, timing and sequence of operations in patients
with synchronous CLM do need to be tailored based on patient-,
surgeon- and hospital-specific factors. In particular, patients with
locally advanced rectal cancer may benefit from a staged liver-first
approach.11,25 As these patients are often treated with neoadjuvant
chemotherapy, a liver-first approach may prevent a delay in
hepatic resection. In the current cohort, all of the patients who
underwent a liver-first approach had a primary rectal tumour and
many received neoadjuvant chemotherapy. In fact, on multivari-
ate analysis, the only factor associated with a higher likelihood of
receiving neoadjuvant chemotherapy was a rectal primary tumour
site (OR 2.46, 95% CI 2.34–3.53; P = 0.004); other patient and
pathological factors, such as age, sex, race, and number and size of
hepatic lesions, were not associated with receipt of neoadjuvant
chemotherapy. Patients with a rectal tumour, those with a large
burden of liver disease requiring two-stage hepatectomy, and
perhaps some patients with marginal performance status, may be
better served by a staged approach. Most patients, however, can
seemingly be managed with a simultaneous surgery approach. As
noted herein, even patients who undergo a major hepatic resec-
tion simultaneously with a colorectal procedure did not have a
higher incidence of complications, including major morbidity.
Patients who underwent a simultaneous approach also had a sig-
nificantly shorter total LoS in the hospital. In addition, in patients
submitted to a ‘classic’ staged approach, hepatectomy for CLMwas
delayed by an average of 4.8 months (IQR: 3–8months).Although
it is difficult to ascribe an oncological impact to this delay, any
delay in the definitive management of CLM – especially one that
may not be necessary – is probably best avoided.As such, although
the surgical plan should be specific to each patient, a simultaneous
surgery approach to the treatment of synchronous CLM seems to
be preferable based on comparable morbidity, mortality and a
shorter total LoS for the patient.
One of the main objectives of the current study was to define
the potential savings to be derived from the use of a simultaneous
versus a staged surgery approach to synchronous CLM. Cost com-
parison analyses of alternative treatment strategies are crucial in
an era of escalating health care expenditures. Several methods are
possible when evaluating the economic impact of treatment. In
the only other published study to compare the economic impacts
of simultaneous and staged resection, respectively, in patients
with synchronous CLM, Abbott et al. utilized Medicare reim-
bursement data to estimate cost differences between the operative
approaches.14 The authors found that a simultaneous approach
resulted in approximately 17.1% lower costs compared with a
staged approach.14 The use of Medicare reimbursement data,
however, is problematic as they pertain to a specific segment of the
population who are covered by one national insurance plan. As
such, the current study sought to further analyse the economic
impact of a simultaneous versus staged approach. Specifically, the
present study is unique in that it utilized actual hospital charges
based on fixed internal fees to determine the economic impact of
treatment. On average, total hospital charges for patients under-
going a simultaneous operation resulted in savings of US$27 824
per patient and were 55.1% lower than the average cost of a staged
surgery approach. Perhaps as expected, increasing extent of
disease (bilateral versus unilateral metastatic disease), as well as
the complexity of the colorectal (low anterior resection versus
right hemi-colectomy) and hepatic (major versus minor hepate-
ctomy) resection resulted in higher overall total charges (Fig. 3).
Furthermore, the incidence of any perioperative complications
resulted in higher total charges. After controlling for these factors,
however, the main driving factor for the higher charges among
patients in the staged surgery cohort was found to refer to the
increased total hospital LoS. Patients in the staged surgery group
spent an average of 13 total days in hospital, whereas those in the
simultaneous surgery group spent an average of 7 total days in
hospital. At an average charge of US$3581 per day, prolonged
overall LoS in the staged surgery group was a main driver of
increased charges. Interestingly, after adjusting for LoS and extent
of hepatectomy and colectomy, total charges remained higher in
the staged approach group. The most likely cause of the increased
marginal charge above the charges associated with each hospital
stay were the added charges associated with a second hospitaliza-
tion, and reflected additional laboratory, radiology, medication
and other miscellaneous charges incurred during a second stay. In
sum, a single simultaneous operation in patients with synchro-
nous CLM was noted to cut the total hospital charges for the
treatment of synchronous CLM by over half of the charge for two
separate staged operations.
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There are several limitations to consider when interpreting
these data. As with all retrospective analyses, selection bias was a
possibility. A subset of patients who underwent a staged approach
underwent the initial colorectal procedure at an outside hospital
and the exact charge data for the procedure at the outside insti-
tution were not available. To account for this, charges for the
colorectal procedure were input using the average charges assessed
for all patients undergoing an equivalent colorectal resection over
the past 5 years at the study institution. Given the large overall
difference found between a simultaneous and staged approach,
the potential difference between actual and inputted data is likely
to have had minimal impact on the overall economic benefit
noted for the simultaneous approach. Although the present analy-
ses utilized hospital charges as opposed to estimating the actual
costs of treatment, all hospital charges were derived from a single
institution and were based on fixed internal fees for each service
provided. Thus, the comparative economic benefit observed with
a simultaneous approach should not be affected by the use of
charge rather than cost data from this institution. Lastly, data on
perioperative morbidity for those colorectal cases performed at an
outside institution among patients in the staged approach group
were also not available. Given that the present study showed com-
parable rates of morbidity between the staged and simultaneous
groups, these missing data would actually have led to an underes-
timation of complications associated with a staged approach
and – if anything – provide further support for a simultaneous
approach to surgery.
In conclusion, patients with synchronous CLM managed with
either a simultaneous or staged approach had comparable
perioperative and longterm outcomes. Patients treated with a sim-
ultaneous approach spent an average of 6 days fewer in hospital. In
turn, a simultaneous approach resulted in a reduction in median
charges of US$27 824, or 55.1% per patient. Therefore, when
appropriate and technically feasible, the simultaneous surgery
approach to synchronous CLM should be preferred as it is safe
and effective, and provides for substantial economic savings.
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